NANOBIOTIX provides business update and reports financial results for the first half of 2024 Page 1

• RT-NBTXR3 followed by anti-PD-1 demonstrated a favorable safety profile, good disease control, and good tumor response in patients who were both anti-PD-1 naive and resistant, suggesting that NBTXR3 can prime the immune system prior to checkpoint therapy.
• Several clinical milestones are expected in the next 12 to 18 months, including updated data on pancreatic cancer and head and neck cancer and initial data on esophageal cancer and lung cancer
• EUR 66.3 million in cash and cash equivalents as of June 30, 2024, with a liquidity reserve extending into the fourth quarter of 2025

PARIS and CAMBRIDGE, Mass., September 18, 2024 (GLOBE NEWSWIRE) – NANOBIOTIX
(Euronext: NANO – NASDAQ: NBTX – the “Company”)an advanced clinical-stage biotechnology company developing breakthrough nanoparticle-based approaches to expand treatment options for patients with cancer and other serious diseases, provided an operational progress update and announced its half-year financial results for the six-month period ended June 30, 2024.

“We continue to make strong progress in advancing our nanoparticle-based therapeutic approach with lead candidate NBTXR3, which is part of our global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company. The agreement is expected to realize significant therapeutic and commercial opportunities in solid tumors worldwide, starting with lung and head and neck cancer. As part of our ongoing collaboration with MD Anderson, we continue to create additional expansion opportunities in several cancer areas,” said Laurent Levy, co-founder of Nanobiotix and Chief Executive Officer. “The potential of NBTXR3 to stimulate immune activity prior to an anti-PD-1 inhibitor was further supported by new data from Study 1100 presented at the American Society for Clinical Oncology (ASCO) Annual Meeting. These demonstrate disease control and tumor response in patients with head and neck cancer who are naive or resistant to prior anti-PD-1 therapy.” We expect several clinical milestones in the next 12-18 months that will further advance and expand the potential patient base for NBTXR3, including updated data in pancreatic cancer and head and neck cancer and initial data in esophageal cancer and lung cancer.”